New therapeutic options for metastatic malignant insulinomas

W.W. de Herder, Ellen Schaik, Dik Kwekkeboom, R.A. Feelders

Research output: Contribution to journalArticleAcademicpeer-review

49 Citations (Scopus)

Abstract

Insulinomas are the most common, functioning, pancreatic neuroendocrine tumours. The great majority (>90%) of insulinomas are nonmetastatic at presentation and can be surgically cured. The <10% patients with distant (liver-bone) metastases have a median survival of <2 years. Everolimus and sunitinib have been recently introduced as targeted therapies for metastatic pancreatic neuroendocrine tumours. An additional advantage of everolimus in the treatment of patients with metastatic insulinomas is its capability to increase blood glucose levels. Peptide receptor radiotherapy using radiolabelled somatostatin analogues has also been shown to be successful in controlling tumour growth of metastatic pancreatic neuroendocrine tumours. In patients with metastatic insulinomas, this therapeutic modality was also effective in controlling hypoglycaemia, even in the presence of tumour regrowth. With the introduction of these new therapeutic modalities, the therapeutic arsenal for the 'tailor-made' approach of patients with metastatic insulinomas is further expanded.
Original languageUndefined/Unknown
Pages (from-to)277-284
Number of pages8
JournalClinical Endocrinology
Volume75
Issue number3
DOIs
Publication statusPublished - 2011

Cite this